Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Celgene Corporation |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00675441 |
Primary:
Secondary:
Condition | Intervention | Phase |
---|---|---|
Graft-Versus-Host Disease |
Drug: Lenalidomide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Versus-Host Disease (GVHD) |
Estimated Enrollment: | 46 |
Study Start Date: | April 2008 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Lenalidomide
|
Drug: Lenalidomide
10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Amin Alousi, MD | 713-792-8750 |
United States, Texas | |
U.T. M.D. Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Principal Investigator: Amin Alousi, MD |
Principal Investigator: | Amin Alousi, MD | U.T.M.D. Anderson Cancer Center |
Responsible Party: | U.T. M.D. Anderson Cancer Center ( Amin Alousi, MD/Assistant Professor ) |
Study ID Numbers: | 2006-0321 |
Study First Received: | May 7, 2008 |
Last Updated: | December 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00675441 |
Health Authority: | United States: Institutional Review Board |
Chronic Graft-versus-Host Disease cGVHD GVHD Lenalidomide Revlimid CC-5013 Stem Cell Transplant Allogeneic hematopoietic stem cell transplantation |
Allogeneic HSCT HSCT Post-Transplant Prophylactic Immunosuppressive Therapy Steroids Standard-of-care steroid treatment Corticosteroids Prednisone Medrol |
Prednisone Methylprednisolone Graft versus host disease Prednisolone Lenalidomide |
Methylprednisolone acetate Graft vs Host Disease Prednisolone acetate Methylprednisolone Hemisuccinate Homologous wasting disease |
Immune System Diseases Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |